New York Life Investment Management LLC Immunovant, Inc. Transaction History

New York Life Investment Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$31.31 - $44.19 $15,091 - $21,299	-482 Reduced 2.1%	22,438 $945,000
Q3 2023 Nov 07, 2023	SELL	$18.55 - $39.96 $67,744 - $145,933	-3,652 Reduced 13.74%	22,920 $879,000
Q2 2023 Aug 04, 2023	SELL	$14.2 - $23.75 $49,685 - $83,101	-3,499 Reduced 11.64%	26,572 $504,000
Q1 2023 May 08, 2023	SELL	$15.27 - $19.72 $1.11 Million - $1.44 Million	-72,884 Reduced 70.79%	30,071 $466,000
Q4 2022 Feb 10, 2023	BUY	$6.59 - $17.75 $76,523 - $206,113	11,612 Added 12.71%	102,955 $1.83 Million
Q3 2022 Nov 10, 2022	BUY	$3.93 - $6.37 $26,362 - $42,729	6,708 Added 7.93%	91,343 $510,000
Q2 2022 Aug 12, 2022	BUY	$3.38 - $5.65 $286,066 - $478,187	84,635 New	84,635 $330,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of New York Life Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on New York Life Investment Management LLC with notifications on news.